학술논문
Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
0732183X